Studies have shown that specific gene variations make women more susceptible to lung cancer, even without smoking.

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Patients with appendiceal adenocarcinoma have a 7.5% risk of second primary cancer within 10 years. There is a 12% excess incidence of secondary primary cancers, particularly colorectal, in these ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...

Treating initially unresectable gastric or GEJ cancer with camrelizumab plus nab-POF led to an R0 resection rate of 75% in a phase 2 trial.